This archive report was first published on 16 November 2019.
The European Medicines Agency (EMA) has officially opened its new headquarters in Amsterdam, Netherlands, marking a significant milestone in the relocation process following the UK's decision to leave the European Union.
Costing 300 million euros ($330 million), the state-of-the-art building boasts an impressive 16-storey high wall of 54,000 plants and a rooftop bar, providing a unique and relaxing environment for the agency's staff.
As of November 2017, the EMA had announced its decision to relocate from London to Amsterdam, with the agency's chief, Guido Rasi, admitting that the move was 'painful' for staff members who had to leave behind their families, jobs, and friends.
However, Rasi expressed confidence that the relocation would not lead to a shortage of medicines on both sides of the Channel, a major concern following the Brexit vote.
According to Medical Care and Sport Minister Bruno Bruins, the EMA's relocation has been a fruitful outcome for the Netherlands, with around 100 international companies having moved to the country so far due to Brexit, and over 300 others expressing interest.
As the EMA settles into its new home, staff members are adjusting to life in Amsterdam, with some finding it challenging to adapt to the city's notorious property rental prices and Dutch weather.
Despite these challenges, the EMA's relocation is seen as a significant boost to the Netherlands' economy, with the agency's presence expected to attract other institutions and companies to the country.
